Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus

Next Previous
Trial Profile

A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARO ALK7 (Primary) ; Tirzepatide
  • Indications Metabolic disorders; Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Acronyms AROALK7-1001
  • Sponsors Arrowhead Pharmaceuticals

Most Recent Events

  • 05 Jun 2025 Planned number of patients changed from 90 to 126.
  • 05 Jun 2025 Planned End Date changed from 31 Aug 2027 to 10 Dec 2026.
  • 05 Jun 2025 Planned primary completion date changed from 31 Aug 2027 to 10 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top